Ask any analytical chemist which hyphenated technique has become indispensable over the past decade, and the answer will almost certainly be the same: tandem chromatography–mass spectrometry. Whether it is <a target="_blank" rel="noopener noreferrer" href="https://www.organomation.com/preparing-samples-for-lc-ms/ms-analysis">LC–MS/MS</a> quantifying a novel biologic’s metabolic fate, or <a target="_blank" rel="noopener noreferrer" href="https://www.organomation.com/preparing-samples-for-gc-ms/ms-analysis">GC–MS/MS</a> chasing per- and polyfluoroalkyl substances (PFAS) down to sub-part-per-trillion levels in municipal water, the combination of chromatographic separation with the specificity of tandem mass detection has become the analytical workhorse of choice across virtually every regulated sector.Below we examine the key forces propelling this expansion, from biopharma pipeline dynamics and PFAS regulatory mandates to AI-driven automation and reshoring of pharmaceutical manufacturing—and explore what each trend means for laboratories managing sample preparation and analytical workflows.<h3>Biopharma: The Engine Room of LC–MS/MS Demand</h3><h4>GLP-1 Agonists and the Metabolomics Gold Rush</h4>The explosive commercial and scientific interest in GLP-1 receptor agonists—<a target="_blank" rel="noopener noreferrer" href="https://www.sepscience.com/advancing-glp-1-peptide-analysis-chromatography-challenges-and-innovations-12163">semaglutide and related peptide therapeutics </a>for diabetes and obesity—has dramatically expanded the analytical demands placed on tandem MS platforms. Discovery programs require precise quantification of peptide drug candidates and endogenous biomarkers across complex biological matrices. These workflows rely on high-sensitivity LC–MS/MS for pharmacokinetic profiling, receptor occupancy studies, and metabolomics characterization. Metabolomics is, in fact, projected to be the fastest-growing application segment in mass spectrometry, driven in part by its growing role in cancer screening, biomarker discovery, and metabolic disease research.I have been spending more time learning about GLP-1s because this is the hot topic that people want to discuss on the Concentrating on <a target="_blank" rel="noopener noreferrer" href="https://open.spotify.com/show/1wZg67rCjoGju4yhqxI3tL?si=n9GLz9zjSCOrVfXPxFPhng&amp;nd=1&amp;dlsi=52868e027aad4d22">Chromatography podcast</a>. With that said, I was astounded looking at CNBC.com during breakfast this morning to see that <a target="_blank" rel="noopener noreferrer" href="https://www.cnbc.com/2026/03/21/glp-1-diets-restaurants-protein-fiber-weight-loss-drugs.html">one in eight Americans are currently taking one of these drugs such as Ozempic</a>.<h4>Antibody–Drug Conjugates and Gene Therapy: Complexity at Every Step</h4>The ascent of antibody–drug conjugates (ADCs) and gene therapies has introduced a new level of analytical complexity. ADCs blend the target specificity of monoclonal antibodies with the cytotoxic potency of small-molecule payloads—and characterizing the linker chemistry, drug-to-antibody ratio (DAR), and conjugate stability demands high-resolution LC–MS/MS at every stage from discovery through QC release testing. Gene therapy vectors require equally rigorous characterization of impurities, aggregates, and empty/full capsid ratios.This translates into a direct need for low-evaporation, high-recovery concentration methods that preserve labile protein structures and maintain sample integrity prior to LC–MS/MS injection. <a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/article/5392">Nitrogen evaporation workflows</a> that minimize oxidative stress and maintain sample temperature are increasingly critical in these pipelines.<h4>Precision Medicine and Multi-Omics Integration</h4>The shift toward precision medicine has accelerated adoption of high-throughput, multi-analyte MS platforms. Proteomics, metabolomics, and lipidomics workflows are converging on a single analytical platform—tandem MS—and generating datasets of a scale and complexity that were unimaginable ten years ago.Make no mistake: the triple quadrupole serves an irreplaceable role in quantitative targeted analysis. At the same time, <a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products?category=134&amp;manufacturerItems=3">Orbitrap </a>and Q–TOF hybrid platforms are growing rapidly as researchers demand full-scan accurate mass for untargeted discovery.<h3>Environmental Mandates: PFAS Testing Drives Adoption</h3>Environmental testing is something that every person, chemist or not, can understand the importance of. Mounting mandates from the U.S. Environmental Protection Agency and European regulators regarding PFAS—the “forever chemicals” whose extraordinary environmental persistence is matched only by the analytical challenge of detecting them at trace levels—have created immediate, compliance-driven investment in LC–MS/MS infrastructure.<h4>The Regulatory Framework Chemists Need to Know</h4>The EPA has codified a suite of LC–MS/MS-based methods as the analytical standard for PFAS in water and solid matrices:<ul><li><a target="_blank" rel="noopener noreferrer" href="https://blog.organomation.com/blog/epa-533-drying-down-pfas-samples-after-spe">EPA Method 533</a>: Weak anion exchange SPE combined with LC–MS/MS; covers 25 PFAS including short-chain compounds in drinking water.</li><li><a target="_blank" rel="noopener noreferrer" href="https://blog.organomation.com/blog/sample-concentration-epa-method-537-pfas-determination">EPA Method 537.1</a>: Reversed-phase SPE followed by LC–MS/MS; covers 18 PFAS including the GenX compound, with method detection limits in the low ng/L range.</li><li><a target="_blank" rel="noopener noreferrer" href="https://www.agilent.com/en/solutions/environmental/water-testing/pfas-in-water/us-epa-method-8327?srsltid=AfmBOooCY1pcavj7B1PH-75d3HO4BGDglNlhmyTyrpDY3zvUksMO1dlg">EPA Method 8327</a>: LC–MS/MS for selected PFAS in prepared extracts of aqueous and solid matrices.</li><li><a target="_blank" rel="noopener noreferrer" href="https://blog.organomation.com/blog/preparing-diverse-sample-matrices-for-epa-method-1633">EPA Draft Method 1633</a>: The emerging benchmark for PFAS in non-aqueous matrices—aqueous, solid, biosolids, and tissue—quantifying up to 40 PFAS.</li></ul>All of these methods designate LC–MS/MS, specifically LC coupled to triple quadrupole or tandem-in-time platforms operating in negative electrospray ionization mode with multiple reaction monitoring (MRM), as the required or recommended analytical technique. PFAS analysis is, at its core, an LC–MS/MS problem.<h4>The Sample Preparation Bottleneck</h4>Chemists who have worked with PFAS methods understand the particular demands they place on sample preparation. The ubiquity of<a target="_blank" rel="noopener noreferrer" href="https://blog.organomation.com/blog/tackling-pfas-contamination-practical-insights-from-epa-537.1-method-development"> PFAS in laboratory materials</a>—PTFE tubing, some SPE sorbents, standard bench supplies—means that blank contamination control is as analytically demanding as the detection itself. EPA 537.1 requires that sample volumes of approximately 250 mL be extracted and reconstituted in as little as 1 mL, creating a 250:1 concentration factor that can expose even trace contamination in the sample processing chain. The installation of a delay column between the LC pump and autosampler to prevent instrument background interference is now standard practice.This is precisely where robust, <a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/article/5385">inert nitrogen evaporation </a>systems earn their keep. PFAS workflows that use nitrogen-assisted evaporation to concentrate extracts prior to reconstitution benefit from materials that avoid PTFE and other fluoropolymers that can leach PFAS background—a consideration Organomation addresses in its concentration system designs.The analytical community is also moving beyond targeted PFAS analysis. High-resolution accurate mass (HRAM) spectrometry via Orbitrap technology, paired with non-targeted screening workflows, is gaining traction for the identification of the more than 5,000 currently catalogued PFAS compounds and the novel structures that continue to emerge. LC–MS/MS remains the quantitative gold standard; HRAM provides the discovery layer.<h3>Technological Trends Reshaping the LC–MS/MS Workflow</h3><h4>Artificial Intelligence and Automated Data Interpretation</h4>The datasets generated by modern tandem MS platforms—particularly in omics applications—are too large and too complex for conventional manual review. AI-driven spectral deconvolution, automated peak integration, and AI-assisted hypothesis generation are now embedded in the software suites accompanying leading instruments. <a target="_blank" rel="noopener noreferrer" href="https://www.agilent.com/about/newsroom/presrel/2022/17feb-gp22004.html?srsltid=AfmBOop3warRIaEojXM2YyMML6RXfMIDzE-Wm0h-SiKkkocBeeET2m7u">Agilent’s acquisition of Virtual Control’s ACIES </a>software specifically to automate LC–MS and GC–MS data analysis is emblematic of this direction.For laboratory managers, AI integration means smaller specialized teams can operate high-throughput multi-analyte workflows—but it also means that the front-end sample preparation must be even more reproducible, since algorithmic interpretation amplifies inconsistencies introduced upstream.<h4>Online SPE Coupling and “Chromatography Without Walls”</h4>A significant trend is the integration of solid-phase extraction directly into the HPLC flow path—so-called online SPE–HPLC coupling. Systems that combine extraction and chromatographic separation in a single analytical instrument reduce manual transfer steps, minimize the risk of sample loss or contamination, and dramatically increase throughput. For analytes at very low concentrations, online SPE provides the on-column concentration capability that traditional offline preparation achieves with manual evaporation steps.That said, offline sample preparation—including <a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/article/5392">nitrogen-assisted evaporation</a> under controlled conditions, <a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2407">liquid–liquid extraction</a>, and protein precipitation—retains significant advantages in flexibility, matrix handling, and the ability to process sample volumes that exceed online system capacity. The two approaches are increasingly complementary rather than competitive in well-designed analytical laboratories.<h4>High-Purity Solvents and Reference Materials</h4>As detection limits push further into the femtogram range and regulatory methods demand demonstrable blank performance, the quality of analytical consumables—mobile phase solvents, derivatization reagents, reference standards—has moved from background consideration to front-of-mind. Method validation in regulated environments now routinely requires vendor certification of solvent purity at a level that directly interfaces with instrument performance.<h3>The Ever-Present Need for Sample Evaporation</h3>As LC–MS/MS methods push detection limits lower, the analytical burden shifts increasingly upstream. The quality of the concentration, cleanup, and reconstitution steps preceding injection determines whether the instrument’s theoretical sensitivity is achievable in practice.Several specific developments are particularly relevant:<ul><li>ADC and gene therapy characterization workflows require gentle, low-temperature evaporation that preserves protein structure and prevents aggregation prior to LC–MS/MS. Nitrogen evaporation under controlled conditions is the preferred approach.</li><li>PFAS trace analysis demands evaporation systems constructed from PFAS-inert materials, with rigorous attention to avoiding fluoropolymer surfaces throughout the sample path.</li><li>High-throughput pharmaceutical QC driven by reshoring demands parallel processing capability—multi-position evaporators that maintain consistent flow and temperature across all positions simultaneously.</li><li>Multi-omics and metabolomics workflows generate large sample batches that benefit from automated, walk-away evaporation with programmable endpoints to ensure reproducible final volumes across a cohort.</li></ul>Tandem chromatography–mass spectrometry is not merely growing; it is becoming structurally embedded in the analytical workflows of every major regulated industry. The convergence of biopharma complexity, PFAS regulatory mandates, AI-enabled data analysis, and pharmaceutical reshoring is creating a multi-year demand cycle that will require laboratories to invest not only in instruments, but in the entire sample preparation ecosystem that makes those instruments perform.For analytical chemists, the practical takeaway is this: as mass spectrometry sensitivity continues to advance, the sample preparation step becomes the binding constraint on method performance. Whether you are developing a new PFAS method to meet EPA 1633, characterizing an ADC’s drug-to-antibody ratio, or running a 500-sample metabolomics cohort overnight, the reliability and cleanliness of your concentration and cleanup workflow determines the quality of every data point that follows.&nbsp;

The Continued Rise of Tandem Chromatography–Mass Spectrometry

<h3>A Practical Guide to Getting the Most from Syringe Filters: Tips, Tricks, and Common Pitfalls</h3>Syringe filters play a crucial role in chromatography and many other laboratory applications by removing particulate matter before analysis. Proper sample filtration helps protect analytical instruments, extends column lifetime, and improves data quality. However, selecting an unsuitable filter—or using one incorrectly—can introduce contamination, reduce filtration efficiency, or even compromise analytical results. The following recommendations will help you avoid common mistakes and ensure reliable filtration every time.<img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/KNAUER_Avoiding_Common_Syringe_Filter_Mistakes_3_150e8c1c2b.webp" alt="KNAUER: Avoiding Common Syringe Filter Mistakes" srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_KNAUER_Avoiding_Common_Syringe_Filter_Mistakes_3_150e8c1c2b.webp 133w," sizes="100vw" width="1276" height="1496"><h4>1. Improper Filter Handling</h4>Using excessive force during filtration or attempting to reuse disposable syringe filters can damage the membrane and increase the risk of sample contamination.<ul><li>Solution: Apply slow, even pressure throughout the filtration process and always dispose of single-use filters after one use. If the flow rate decreases noticeably, replace the filter instead of applying additional force.</li></ul><h4>2. Selecting an Inappropriate Pore Size</h4>Using the wrong pore size may either fail to remove unwanted particles or cause the membrane to clog prematurely, reducing filtration efficiency.<ul><li>Solution: A 0.45 µm membrane is generally suitable for routine particulate removal, while a 0.22 µm membrane is recommended for finer filtration and bacterial removal. Samples with higher viscosity may require a pre-filter to prevent rapid clogging. It is also important to consider the intended analytical technique. For example, 0.22 µm filters are typically preferred for UHPLC and LC-MS applications, whereas 0.45 µm filters are often sufficient for conventional HPLC analyses.</li></ul><h4>3. Choosing the Wrong Membrane Material</h4>Different membrane materials exhibit different chemical resistance. Using an incompatible membrane may lead to degradation of the filter, sample contamination, or complete filtration failure.<ul><li>Solution: Always verify solvent compatibility before filtration. PTFE membranes are an excellent choice for organic solvents, while PES and nylon membranes are better suited to aqueous samples. If compatibility is uncertain, perform a small-scale trial before filtering valuable samples.</li><li>Pro Tip: For additional guidance, see our blog article "How to Choose the Right Membrane for your Syringe Filter", which provides a detailed comparison of membrane materials and their recommended applications.</li></ul><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/KNAUER_Avoiding_Common_Syringe_Filter_Mistakes_2_e47021fb11.jpg" alt="KNAUER Sepapure® Syringe Filters are available with multiple membrane materials, each identified by a dedicated color code for quick and reliable selection." srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_KNAUER_Avoiding_Common_Syringe_Filter_Mistakes_2_e47021fb11.jpg 245w," sizes="100vw" width="1580" height="902"><h4>4. Ignoring Filter Capacity</h4>Using a filter with insufficient capacity can result in rapid membrane blockage, increasing filtration time and reducing laboratory productivity.<ul><li>Solution: When filtering larger sample volumes, choose high-capacity syringe filters or introduce a pre-filtration step. Never force liquid through a clogged membrane, as doing so may damage the filter and negatively affect sample quality.</li></ul><h4>5. Overlooking Sample Adsorption</h4>Certain membrane materials may adsorb analytes of interest, leading to lower recoveries and potentially affecting quantitative results.<ul><li>Solution: For protein samples or other adsorption-sensitive analytes, select membranes with low binding characteristics, such as nylon or glass fiber, whenever appropriate. Performing a small recovery test before routine analysis can help identify potential analyte losses.</li></ul><h4>6. Failing to Optimize Filtration Performance</h4>Slow filtration is more than just an inconvenience—it often indicates that the filtration conditions are not optimal.<ul><li>Solution: If filtration becomes unusually slow, investigate possible causes such as membrane clogging, excessive sample viscosity, or an unnecessarily small pore size. Depending on the sample, dilution or sequential filtration using progressively finer filters may significantly improve performance.</li></ul><h4>Final Thoughts</h4>Selecting the appropriate syringe filter is a straightforward process, but overlooking small details can have a significant impact on analytical performance. Choosing the correct membrane material, pore size, and filtration strategy helps improve laboratory efficiency, protects chromatography systems and columns, and contributes to accurate, reproducible analytical results.With the right syringe filter and proper filtration technique, you can minimize sample preparation problems and maximize confidence in every analysis.<img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/KNAUER_Avoiding_Common_Syringe_Filter_Mistakes_4_983a15e289.jpg" alt="KNAUER: Sepapure® Syringe Filter Selection" srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_KNAUER_Avoiding_Common_Syringe_Filter_Mistakes_4_983a15e289.jpg 245w," sizes="100vw" width="1160" height="627">Happy filtering!

Avoiding Common Syringe Filter Mistakes

News from LabRulezLCMS Library - Week 27, 2026

Article

Product

Application

Academy

Poster

Everything from the world of analytical chemistry in one place. We connect people in solving their problems. At Labrulez you will find all the necessary information easily, quickly and clearly. Stop searching and start finding.

LabRulez

Organomation, founded in 1959, designs and manufactures high-quality nitrogen evaporators and extraction systems. Known for innovation and durability, their lab instruments are used globally for efficient sample preparation with strong customer support.

Organomation

Based in Berlin, KNAUER is a medium-sized, owner-managed company that has been serving the sciences since 1962. We develop and manufacture scientific instruments of superior quality for liquid chromatography, including: Analytical HPLC/UHPLC, Preparative HPLC, Fast protein liquid chromatography (FPLC), Multi-column chromatography/Simulated moving bed (SMB) chromatography. High pressure dosing, in-line detection systems, and osmometry are additional business areas.

KNAUER

The Analytical Scientist

Agilent Technologies

Bruker

Thermo Fisher Scientific

C&EN

SCIEX

Waters Corporation

Ion Mobility (IM) advancements in Software, Data Bases, AI and Machine learning are quickly improving capabilities to make unknown identifications, separate and ID isomers, as well as improve workflows associated with metabolomics, lipidomics, PFAS, and qual-quant screening.
In addition, IM measurements are significantly improved with HRdm High Resolution Demultiplexing. This is the first commercial IM instrument to enable the simultaneous combination of high drift resolution, while at the same time achieving all four of the following measurement capabilities: broad mass range in a single injection, multiplexing to increase sensitivity, compatibility with fast chromatographic acquisition rates , and highest precision in CCS measurements. For more accurate CCS predictions, the better precision in the CCS training set improves AI machine learning SW. This can significantly reduce the number of potential candidate structures to select from when making unknown identifications.
<blockquote>
Presenter: Brock Juliano (Ph.D. student, Brandon Ruotolo lab, Dept of Chemistry, Univ of Michigan)
</blockquote>

Agilent Technologies: Development of RapidFire Native Mass Spectrometry and Collision Induced Unfolding Methodologies for High Throughput Screening of Protein and Oligonucleotide Biotherapeutics.

Development of RapidFire Native Mass Spectrometry and Collision Induced Unfolding Methodologies for High Throughput Screening of Protein and Oligonucleotide Biotherapeutics.

Development of RapidFire Native Mass Spectrometry and Collision Induced Unfolding Methodologies for High Throughput Screening.

RapidFire Native MS of Proteins and Oligonucleotides

Welcome to The Analytical Scientist’s Trends and Challenges in PFAS Analysis forum!
Per- and poly-fluorinated alkyl substances, or PFAS, are a family of synthetic substances used in everyday products, such as stain and grease-repellent coatings and have appeared in almost all foods and drinking water. Toxic at extremely low levels, regulators demand low detection limits, and the list of PFAS compounds under investigation continues to expand. 
We recently asked our readers for their thoughts on the challenges involved in PFAS analysis, whether current methods are up to the task, and what analytical advances may be on the horizon. 
Here, our panel of experts will discuss the survey findings and share their perspectives on the latest trends and best practices in PFAS analysis. 
The event will have three parts: 
<ul>
<li>Part I: A discussion of the results of our recent vendor-neutral audience survey (10-15 minutes).
</li>
<li>Part II: Technology/application-focused presentations from each of our speakers (15 minutes each).
</li>
<li>Part III: A chance for you to ask our speakers questions as part of an audience Q&amp;A (15 minutes).
</li>
</ul>
<blockquote>
Presenter: Day Powell (Environmental Application Specialist , Agilent)
</blockquote>
<blockquote>
Day has worked for Agilent as an Environmental Specialist for one year. Before this he worked for a major UK Water company (United Utilities) as a senior analyst responsible for developing new methodologies for both LC/MS and GC/MS applications.
</blockquote>
<blockquote>
Day has analysed PFAS for several years and helped United Utilities to gain UKAS accreditation for determining 47 PFAS by LC/MS in drinking water using direct injection to address the latest Drinking Water Inspectorate (DWI).
</blockquote>
<blockquote>
Presenter: Marcus Chadha (EMEA Applications Specialist Manager, Agilent) Dr. Marcus Chadha has worked for Agilent for seven years where he first worked as an LC/MS Field Application Specialist before moving on to being the EMEA Applications Specialist Manager in 2021.
</blockquote>
<blockquote>
In his roles he has collaborated with our Environmental and Food customers, developed new methods, and trained LC/TQ and LC-Q/TOF MS workflows to new and existing customers.
</blockquote>
<blockquote>
He now coordinates these activities using his team of GC/MS and LC/MS application specialists. Marcus is also responsible for the market specialisation activities for the environmental market across Europe.
</blockquote>
<blockquote>
Presenter: Linx Waclaski (Product Manager for Ion Chromatography, Metrohm USA)
</blockquote>
<blockquote>
Linx Waclaski is the Product Manager for Ion Chromatography at Metrohm USA, in Riverview, Florida. He has years of experience in multiple chromatographic techniques, including ion chromatography, gas chromatography, liquid chromatography, and mass spectrometry, with extensive experience in R&amp;D and applications development.
</blockquote>
<blockquote>
His chromatography applications experience extends across environmental, food safety, and life sciences industries. He has an M.S. in Forensic Science from Duquesne University.
</blockquote>
<blockquote>
Presenter: Ruth Marfil-Vega (Senior Market Manager - Environmental, Shimadzu)
</blockquote>
<blockquote>
Dr. Ruth Marfil-Vega has 20 years of expertise in environmental chemistry and engineering in the US and Europe. She has worked with the EPA and the utilities industry to design and execute comprehensive solutions for addressing new environmental and water quality issues, including PFAS, regulated and unregulated DBPs, and other emerging contaminants.
</blockquote>
<blockquote>
Since Ruth joined Shimadzu five years ago, she has continued to work with environmental stakeholders to ensure that analytical instrumentation and workflows support their success.
</blockquote>
<blockquote>
She earned a BSc in Chemistry from the University of Valladolid (Spain) and a PhD in Environmental Science and Engineering from the University of Cincinnati.
</blockquote>

Agilent Technologies: Trends and Challenges in PFAS Analysis

Trends and Challenges in PFAS Analysis

Survey findings and perspectives on the latest trends and best practices in PFAS analysis.

Glycosylation plays a crucial role in determining the pharmacological properties of biotherapeutics. The molecular heterogeneity of glycosylated biotherapeutics makes it difficult to provide thorough characterization of intact glycoproteins by mass spectrometry.
Current methods for analyzing biotherapeutics only measure fragments of the compound or rely on partial digestion of the glycans to reduce sample complexity. These limitations pose important risks and challenges for biotechnology companies that need to report human-compatible and consistent glycosylation, critical for drug safety and efficacy. 
We will present a new approach to glycoform fingerprinting that uses proton-transfer charge-reduction with gas-phase fractionation to analyze intact glycoproteins by mass spectrometry. The method provides a detailed landscape of the intact molecular weights present in biotherapeutic protein preparations in a single experiment and offers insights into glycoform composition when coupled with a suitable bioinformatic strategy. In addition, we highlight the application of charge detection native mass spectrometry (Direct Mass Technology mode) towards the elucidation of masses and aggregation of heterogeneous glycosylated biotherapeutics. 
Key Learning Objectives:
<ul>
<li>How to elucidate masses from heterogeneous glycosylated biotherapeutics 
</li>
<li>Learn how proton transfer charge reduction (PTCR) can simplify complex protein mixtures 
</li>
<li>Learn when to use PTCR based methods compared to Direct Mass Technology mode for analysis of biotherapeutics
</li>
</ul>
Who Should Attend:
<ul>
<li>Laboratory Managers 
</li>
<li>Biopharmaceutical Researchers 
</li>
<li>Protein Scientists
</li>
</ul>
<blockquote>
Presenter: Wendy Sandoval (Director, Translational Mass Spectrometry, Genentech)
</blockquote>
<blockquote>
Presenter: Ann Thayer (Contributing Editor, C&amp;EN Media Group)
</blockquote>

C&EN: Direct Analysis of Glycosylated Therapeutics

Direct Analysis of Glycosylated Therapeutics

New approach to glycoform fingerprinting that uses proton-transfer charge-reduction with gas-phase fractionation to analyze intact glycoproteins.

Mass Spectrometry Imaging (MSI) is a technique that allows chemical information to be obtained directly or via the use of matrices from a wide range of surfaces. MS Imaging provides information on the spatial distribution of molecules at or near the surface. Imaging provides beautiful and information-rich images that allow scientists to answer the fundamental question: “Where is this component in my sample?”
In this webinar series, we will examine the basics of MS imaging, compare the techniques of untargeted and targeted MS Imaging and the information that can be gained from each, and end with an interview from Dr. Ryan Leib (Stanford University) and Dr. Roy Martin (Waters Corporation) on the practicalities of setting up a MS Imaging Core lab.
Who Should Attend: Any scientist, lab managers or lab directors looking to expand (or refresh) their knowledge of MS Imaging.
<h3>Part Two – October 17th, 2023: Untargeted versus Targeted Imaging</h3>
In the second session, we will look at the differences between untargeted and targeted imaging: the systems on which the data can be acquired, what data is collected using each technique, how data can be analyzed and how they can work together to provide a complete picture.
<blockquote>
Presenter: Anthony Midley (Principal Applications Support Scientist, Waters Corporation)
</blockquote>
<blockquote>
Anthony Midey is a Principal Applications Support Scientist in Waters Biomedical Research group at Americas Application Laboratory, providing pre- and post-sales support in DESI, MALDI, and imaging mass spectrometry. He is also the BMR team lead for targeted metabolomics and lipidomics LC-MSMS applications. Anthony received his Ph.D. in spectroscopy and mass spectrometry from the University of Rochester and joined Waters in 2015. He has over 55 publications in peer-reviewed journals, with over 10 years working in the analytical instruments sector.
</blockquote>
<blockquote>
HOST: Kieron Faherty, Ph.D. (Separations and Mass Spectrometry Field Marketing Manager, Waters Corporation)
</blockquote>
<blockquote>
Kieron Faherty is the Separations and Mass Spectrometry Field Marketing Manager for the Americas at Waters Corporation. He received his B.Sc. (Hons) in Chemistry from the University of Reading (Reading, Berkshire, UK) and his doctorate in Chemistry from the University of Massachusetts (Amherst, MA). He has held several field-based positions at Waters, most recently as a Field Applications Specialist focused on biopharmaceutical applications using Time-of-Flight mass spectrometry instrumentation.
</blockquote>

Waters Corporation: Untargeted versus Targeted Imaging

Untargeted versus Targeted Imaging

We will look at the differences between untargeted and targeted MS imaging.

Are you ready to propel drug development and revolutionize the pharma industry?
On the quest to develop more effective drugs, the synergy between technology providers and scientists is paramount. Together, they generate reliable and reproducible results, accelerating new chemical entities through the pipeline. From research to commercialization, a continuous cycle of tests and workflows shapes the future, determining your success.
Discover new possibilities:
Unlock the potential of cutting-edge technology and master the art of making the right decisions. The 2-day event brings you interactive expert talks, enriching your knowledge and empowering you to embrace innovative techniques that save precious time at work. From the research of new markers to the drug development moving into non and GLP bioanalysis. Plan your next lab expansion with confidence.
Why attend?
<ul>
<li>Insightful expert talks: engage with 8 prominent speakers and key opinion leaders in the field
</li>
<li>Explore mass spectrometry in pharma: talks about research and quantitation of biomarkers, characterization of metabolites, drug quantitation and nitrosamine impurities, harness the power of mass spectrometry and plan your lab expansion with confidence
</li>
<li>Collaboration and networking: connect with like-minded professionals, share experiences, and build valuable connections within the industry
</li>
<li>Be the forefront of advancements: stay ahead of the competition by gaining insights into the latest trends and advancements in pharma technology
</li>
</ul>
<h3>Agenda Day 1: Wednesday, October 25</h3>
<h5>10:00 - 10:40 The Echo® MS system, a high throughout mass spectrometry, Revolution to accelerate hit finding and drug discovery</h5>
<ul>
<li>Celine Legros and Dany Jeanne Dit Fouque (Eurofins)</li>
</ul>
<h5>10:40 - 11:20 Qualification of lipid biomarker assays using chromatography with triple-quad mass spectrometry</h5>
<ul>
<li>Freddy Oosterbring (Ardena)</li>
</ul>
<h5>11:20 - 11:30 Break</h5>
<h5>11:30 - 12:10 Mass spectrometry, a useful aid in Alzheimer´s disease diagnosis</h5>
<ul>
<li>Jose Antonio Allué (Araclon)</li>
</ul>
<h5>12:10 - 12:50 LC-MS to analyze oligonucleotides: a tool for the characterization of new biotherapeutics</h5>
<ul>
<li>Margalida Artigues (IQS)</li>
</ul>
<h5>12:50 - 13:00 Final notes</h5>
<ul>
<li>Ferran Sanchez (SCIEX)</li>
</ul>
<blockquote>
Presenter: Celine Legros (Drug Discovery, Partnership Director, Eurofins Discovery)
</blockquote>
<blockquote>
Celine Legros, PhD, Drug Discovery Partnership Director, is deeply involved in the design of complex projects, including Hit-Finding, Hit-toLead and Lead-Op programs. Prior to joining Eurofins, Dr. Legros was Scientific Project Leader in the Screening Department at the Institut de Recherches Servier, France, where she was involved in neuroscience, cardio-metabolic diseases, immune-inflammation, and oncology projects, from HTS through to Lead-Optimization. Dr. Legros holds a Ph.D. in Animal Physiology (melatonin circanual rhythm and melatonin receptors) from the University of Tours, France, and completed a postdoctoral fellowship at the Blood Brain Barrier Group at King’s College London, UK.
</blockquote>
<blockquote>
Presenter: Dany Jeanne Dit Fouque (Development Analytic Engineer, Eurofins Cerep)
</blockquote>
<blockquote>
Dany Jeanne dit Fouque, PhD, is a Mass Spectrometry Analytical Development Engineer at Eurofins Cerep. He has 7 years of experience in analytical chemistry with in-depth knowledge in UHPLC-MS/MS method development, enzymatic reaction and MS-Binding using mass spectrometry. Prior to joining Eurofins, he worked in the academic sector on several R&amp;D projects to develop and optimize a new methodology using UHPLC-MSn experiments to identify and quantify isomeric/isobaric compounds in mixture. Dr. Jeanne dit Fouque received his Ph.D. in Mass Spectrometry from the University of Brest, France.
</blockquote>
<blockquote>
Presenter: Freddy Oosterbring (Senior Scientist, Deputy Director Laboratory, Ardena)
</blockquote>
<blockquote>
Freddy Oostebring, Manager Laboratory section chromatography and mass spectrometry at Ardena Bioanalysis. He holds a bachelor degree in Analytical Chemistry and has been working with triple quad mass spectrometry for more than 20 years. His expertise is in the field of method development for the analysis of small molecules, targeted lipids and peptides in biological matrices. Since 2019, he has been a member of the SCIEX Innovation Advisory Board.
</blockquote>
<blockquote>
Presenter: Jose Antonio Allué (Senior Scientist Mass Spectrometry Laboratory, R&amp;D Department, Araclon Biotech S.L., Ph.D. (Pharmacy) University of Barcelona, Spain.)
</blockquote>
<blockquote>
Twenty-five years in the field of Biological Mass Spectrometry, fifteen of them dedicated to research in Alzheimer´s Disease by HPLC-MS/MS (MALDI, IMS-MS, Orbitrap-MS, reTOF-MS, TOF/TOF-MS, Ion-Trap-MS and Triple Quadrupole-MS). Applications of both, targeted and untargeted, proteomic techniques in the fields of immunology, metabolism, pharmacokinetics and pharmacodynamics. Applications of High-Mass MALDI Mass Spectrometry for the analysis of protein complexes and vaccines. Label-free shotgun proteomics by Travelling Wave Ion Mobility Spectrometry coupled to TOF-MS. Applications of MS to the study of amyloid species in tissues and biofluids, including human, dog and transgenic mice models. Research focus: blood and cerebrospinal fluid amyloid biomarkers in Alzheimer´s Disease. Direct analysis of amyloid peptides in blood without immunoprecipitation enrichment.
</blockquote>
<blockquote>
Presenter: Margalida Artigues (Responsable de IQS SCIEX Demo Lab, Instituto Químico de Sarrià IQS)
</blockquote>
<blockquote>
Margalida Artigues earned her Ph.D. in Chemistry in 2019 from Ramon Llull University. She holds a Master&#39;s degree in Analytical Chemistry, as well as a Bachelor&#39;s degree in Chemistry, both from the same university. Since 2021, she has been leading the Mass Spectrometry Laboratory IQS-SCIEX Demo Lab, based in Barcelona, where she is an integral part of the research team at IQS Tech Transfer. In her current role, her mission is to promote research, facilitate technology transfer, and provide support in educational activities related to the LC-MS analytical technique.
</blockquote>
<blockquote>
Presenter: Emiliano de Dominicis (Chemistry Research Director, Mérieux NutriSciences)
</blockquote>
<blockquote>
Emiliano De Dominicis is a researcher with over twenty years of experience in food and pharmaceutical safety, following both private and academic sectors, and he is now Director of Chemical Research - Project Manager at Mérieux NutriSciences. With a Research and Development in Analytical Chemistry dedicated team, Emiliano is responsible for Mérieux NutriSciences Global Research Projects and Scientific Center. Moreover, Emiliano De Dominicis actively participates in funded scientific projects (regional, national and European), scientific congresses as speaker, and writes articles published in specialized scientific journals.
</blockquote>
<blockquote>
Presenter: Lukas Mogler (Sr Group Leader, Extractables and Leachables, Lonza DPS)
</blockquote>
<blockquote>
Dr. Lukas Mogler, Sr Group Leader Extractables and Leachables at Lonza DPS Basel Switzerland. He is a graduated diploma pharmacist holding a PhD from University of Freiburg, Germany. Worked in the field of Forensic Toxicology with focus on mass spectrometry and metabolism studies. Joined Lonza DPS in 2020, responsible for extractables and leachables and elemental impurities assessments.
</blockquote>
<blockquote>
Presenter: Ashwani Gaur (Senior Principal Scientist, Drug Metabolism and Pharmacokinetics, Syngene international Limited)
</blockquote>
<blockquote>
Ashwani Gaur, is Senior Principal scientist in Drug metabolism and Pharmacokinetics department of Syngene international Limited. Ashwani Joined Bioanalytical team in Ranbaxy research Lab soon after completing MS degree in Pharmaceutical Analysis from National Institute of Pharmaceutical Education and Research, India in 2004. Prior to Syngene, he worked in Advinus Therapeutics and Eurofins. Ashwani has contributed to small molecules drug-discovery projects internally and with large and medium size pharmaceutical companies around the globe specifically in lead identification/optimization stages. He leads a team of experts in LC-MS-based bioanalysis of small molecules, metabolites, prodrugs, biomarkers, complex bioanalysis involving chemical derivitisation and exposure determination new modalities like Protacs, ADC`s, oligonucleotides etc. in multiple biological matrices.
</blockquote>

Pharma conclave 2023 (Day 1)

Interactive expert talks, enriching your knowledge and empowering you to embrace innovative techniques that save precious time at work.

Are you ready to propel drug development and revolutionize the pharma industry?
On the quest to develop more effective drugs, the synergy between technology providers and scientists is paramount. Together, they generate reliable and reproducible results, accelerating new chemical entities through the pipeline. From research to commercialization, a continuous cycle of tests and workflows shapes the future, determining your success.
Discover new possibilities:
Unlock the potential of cutting-edge technology and master the art of making the right decisions. The 2-day event brings you interactive expert talks, enriching your knowledge and empowering you to embrace innovative techniques that save precious time at work. From the research of new markers to the drug development moving into non and GLP bioanalysis. Plan your next lab expansion with confidence.
Why attend?
<ul>
<li>Insightful expert talks: engage with 8 prominent speakers and key opinion leaders in the field
</li>
<li>Explore mass spectrometry in pharma: talks about research and quantitation of biomarkers, characterization of metabolites, drug quantitation and nitrosamine impurities, harness the power of mass spectrometry and plan your lab expansion with confidence
</li>
<li>Collaboration and networking: connect with like-minded professionals, share experiences, and build valuable connections within the industry
</li>
<li>Be the forefront of advancements: stay ahead of the competition by gaining insights into the latest trends and advancements in pharma technology
</li>
</ul>
<h3>Agenda Day 2: Thursday, October 26</h3>
<h5>10:00 - 10:40 Case studies from bioanalytical lab in DMPK, Syngene: SCIEX 7500 system and beyond</h5>
<ul>
<li>Ashwani Gaur (Syngene International Ltd)</li>
</ul>
<h5>10:40 - 11:20 Challenges in quantification of NDSRI’s</h5>
<ul>
<li>Dama Venugopal Rao (Dr. Reddy&#39;s Laboratories)</li>
</ul>
<h5>11:20 - 11:30 Break</h5>
<h5>11:30 - 12:10 Nitrosamine impurities in dermal products: from APIs and their salts (secondary amines) evaluations through analytical chemistry and mass spectrometry</h5>
<ul>
<li>Emiliano de Dominicis (Merieux)</li>
</ul>
<h5>12:10 - 12:50 Extractables and leachables assessments in biologics manufacturing</h5>
<ul>
<li>Lukas Mogler (Lonza)</li>
</ul>
<h5>12:50 - 13:00 Final notes</h5>
<ul>
<li>Ferran Sanchez (SCIEX)</li>
</ul>
<blockquote>
Presenter: Celine Legros (Drug Discovery, Partnership Director, Eurofins Discovery)
</blockquote>
<blockquote>
Celine Legros, PhD, Drug Discovery Partnership Director, is deeply involved in the design of complex projects, including Hit-Finding, Hit-toLead and Lead-Op programs. Prior to joining Eurofins, Dr. Legros was Scientific Project Leader in the Screening Department at the Institut de Recherches Servier, France, where she was involved in neuroscience, cardio-metabolic diseases, immune-inflammation, and oncology projects, from HTS through to Lead-Optimization. Dr. Legros holds a Ph.D. in Animal Physiology (melatonin circanual rhythm and melatonin receptors) from the University of Tours, France, and completed a postdoctoral fellowship at the Blood Brain Barrier Group at King’s College London, UK.
</blockquote>
<blockquote>
Presenter: Dany Jeanne Dit Fouque (Development Analytic Engineer, Eurofins Cerep)
</blockquote>
<blockquote>
Dany Jeanne dit Fouque, PhD, is a Mass Spectrometry Analytical Development Engineer at Eurofins Cerep. He has 7 years of experience in analytical chemistry with in-depth knowledge in UHPLC-MS/MS method development, enzymatic reaction and MS-Binding using mass spectrometry. Prior to joining Eurofins, he worked in the academic sector on several R&amp;D projects to develop and optimize a new methodology using UHPLC-MSn experiments to identify and quantify isomeric/isobaric compounds in mixture. Dr. Jeanne dit Fouque received his Ph.D. in Mass Spectrometry from the University of Brest, France.
</blockquote>
<blockquote>
Presenter: Freddy Oosterbring (Senior Scientist, Deputy Director Laboratory, Ardena)
</blockquote>
<blockquote>
Freddy Oostebring, Manager Laboratory section chromatography and mass spectrometry at Ardena Bioanalysis. He holds a bachelor degree in Analytical Chemistry and has been working with triple quad mass spectrometry for more than 20 years. His expertise is in the field of method development for the analysis of small molecules, targeted lipids and peptides in biological matrices. Since 2019, he has been a member of the SCIEX Innovation Advisory Board.
</blockquote>
<blockquote>
Presenter: Jose Antonio Allué (Senior Scientist Mass Spectrometry Laboratory, R&amp;D Department, Araclon Biotech S.L., Ph.D. (Pharmacy) University of Barcelona, Spain.)
</blockquote>
<blockquote>
Twenty-five years in the field of Biological Mass Spectrometry, fifteen of them dedicated to research in Alzheimer´s Disease by HPLC-MS/MS (MALDI, IMS-MS, Orbitrap-MS, reTOF-MS, TOF/TOF-MS, Ion-Trap-MS and Triple Quadrupole-MS). Applications of both, targeted and untargeted, proteomic techniques in the fields of immunology, metabolism, pharmacokinetics and pharmacodynamics. Applications of High-Mass MALDI Mass Spectrometry for the analysis of protein complexes and vaccines. Label-free shotgun proteomics by Travelling Wave Ion Mobility Spectrometry coupled to TOF-MS. Applications of MS to the study of amyloid species in tissues and biofluids, including human, dog and transgenic mice models. Research focus: blood and cerebrospinal fluid amyloid biomarkers in Alzheimer´s Disease. Direct analysis of amyloid peptides in blood without immunoprecipitation enrichment.
</blockquote>
<blockquote>
Presenter: Margalida Artigues (Responsable de IQS SCIEX Demo Lab, Instituto Químico de Sarrià IQS)
</blockquote>
<blockquote>
Margalida Artigues earned her Ph.D. in Chemistry in 2019 from Ramon Llull University. She holds a Master&#39;s degree in Analytical Chemistry, as well as a Bachelor&#39;s degree in Chemistry, both from the same university. Since 2021, she has been leading the Mass Spectrometry Laboratory IQS-SCIEX Demo Lab, based in Barcelona, where she is an integral part of the research team at IQS Tech Transfer. In her current role, her mission is to promote research, facilitate technology transfer, and provide support in educational activities related to the LC-MS analytical technique.
</blockquote>
<blockquote>
Presenter: Emiliano de Dominicis (Chemistry Research Director, Mérieux NutriSciences)
</blockquote>
<blockquote>
Emiliano De Dominicis is a researcher with over twenty years of experience in food and pharmaceutical safety, following both private and academic sectors, and he is now Director of Chemical Research - Project Manager at Mérieux NutriSciences. With a Research and Development in Analytical Chemistry dedicated team, Emiliano is responsible for Mérieux NutriSciences Global Research Projects and Scientific Center. Moreover, Emiliano De Dominicis actively participates in funded scientific projects (regional, national and European), scientific congresses as speaker, and writes articles published in specialized scientific journals.
</blockquote>
<blockquote>
Presenter: Lukas Mogler (Sr Group Leader, Extractables and Leachables, Lonza DPS)
</blockquote>
<blockquote>
Dr. Lukas Mogler, Sr Group Leader Extractables and Leachables at Lonza DPS Basel Switzerland. He is a graduated diploma pharmacist holding a PhD from University of Freiburg, Germany. Worked in the field of Forensic Toxicology with focus on mass spectrometry and metabolism studies. Joined Lonza DPS in 2020, responsible for extractables and leachables and elemental impurities assessments.
</blockquote>
<blockquote>
Presenter: Ashwani Gaur (Senior Principal Scientist, Drug Metabolism and Pharmacokinetics, Syngene international Limited)
</blockquote>
<blockquote>
Ashwani Gaur, is Senior Principal scientist in Drug metabolism and Pharmacokinetics department of Syngene international Limited. Ashwani Joined Bioanalytical team in Ranbaxy research Lab soon after completing MS degree in Pharmaceutical Analysis from National Institute of Pharmaceutical Education and Research, India in 2004. Prior to Syngene, he worked in Advinus Therapeutics and Eurofins. Ashwani has contributed to small molecules drug-discovery projects internally and with large and medium size pharmaceutical companies around the globe specifically in lead identification/optimization stages. He leads a team of experts in LC-MS-based bioanalysis of small molecules, metabolites, prodrugs, biomarkers, complex bioanalysis involving chemical derivitisation and exposure determination new modalities like Protacs, ADC`s, oligonucleotides etc. in multiple biological matrices.
</blockquote>

Pharma conclave 2023 (Day 2)

Mass Spectrometry Imaging (MSI) is a technique that allows chemical information to be obtained directly or via the use of matrices from a wide range of surfaces.
MS Imaging provides information on the spatial distribution of molecules at or near the surface. Imaging provides beautiful and information-rich images that allow scientists to answer the fundamental question: “Where is this component in my sample?”
In this webinar series, we will examine the basics of MS imaging, compare the techniques of untargeted and targeted MS Imaging and the information that can be gained from each, and end with an interview from Dr. Ryan Leib (Stanford University) and Dr. Roy Martin (Waters Corporation) on the practicalities of setting up a MS Imaging Core lab.
Who Should Attend: 
<ul>
<li>Any scientist, lab managers or lab directors looking to expand (or refresh) their knowledge of MS Imaging.</li>
</ul>
<h4>Part Three – October 31st, 2023: Building an MS Imaging Facility</h4>
In the final session of the series, we will have a roundtable with Dr. Ryan Leib (Stanford University) and Dr. Roy Martin (Waters Corporation) where we will discuss the steps necessary to set up an MS imaging core lab and answer questions such as: “who runs this type of lab?” and “who are the main customers?”.
<blockquote>
Presenter: Roy Martin (Principal Field Marketing Manager, Waters Corporation)
</blockquote>
<blockquote>
Dr. LeRoy B. Martin, III is the Principal Field Marketing Manager for Biological Mass Spectrometry at Waters Corporation. His primary role is developing and promoting advanced mass spectrometry solutions in the Americas. He is also charged with evaluating and integrating new technologies and methods in collaborations and product development. Most recently, his focus has been on molecular imaging mass spectrometry and implementation of advances in ion mobility technology. Other research interests include complex mixture quantitative proteomics and structural biology using mass spectrometry. Roy received a BS in Chemistry from Davidson College and a Ph.D. in Analytical Chemistry from North Carolina State University.
</blockquote>
<blockquote>
Presenter: Ryan Leib (Director of Research, Stanford University Mass Spectrometry Laboratory)
</blockquote>
<blockquote>
Ryan Leib is Director of Research for the Stanford University Mass Spectrometry Laboratory. Ryan received his B.S. in Biochemistry from the University of Tulsa (Tulsa, OK), with a focus on LC/MS methods development for natural products discovery. In 2010, he received his Ph.D. in Chemistry from the University of California at Berkeley investigating ionic cluster formation and energetics in Professor Evan Williams’ mass spectrometry laboratory. Prior to joining SUMS in 2014, Ryan developed mass spectrometric analyses for complex mixtures as a Project Leader at SRI International, a non-profit contract R&amp;D firm based in Silicon Valley.
</blockquote>
<blockquote>
Presenter: Kieron Faherty, Ph.D. (Separations and Mass Spectrometry Field Marketing Manager, Waters Corporation)
</blockquote>
<blockquote>
Kieron Faherty is the Separations and Mass Spectrometry Field Marketing Manager for the Americas at Waters Corporation. He received his B.Sc. (Hons) in Chemistry from the University of Reading (Reading, Berkshire, UK) and his doctorate in Chemistry from the University of Massachusetts (Amherst, MA). He has held several field-based positions at Waters, most recently as a Field Applications Specialist focused on biopharmaceutical applications using Time-of-Flight mass spectrometry instrumentation.
</blockquote>

Waters Corporation: Building an MS Imaging Facility

Building an MS Imaging Facility

The steps necessary to set up an MS imaging core lab and answer questions such as: “who runs this type of lab?” and “who are the main customers?”.

During drug metabolite identification (Met ID) studies collision-induced dissociation (CID) is the most commonly used fragmentation technique for LC-MS experiments.
Many conjugation metabolites are found to have multiple bonding potentials to parent drugs. It is a great challenge to locate the bonding sites by CID due to the information lost by highly selective cleavage on these bonds. 
The novel electron-activated dissociation (EAD) is a recently developed technology on the SCIEX ZenoTOF 7600 system. From a single LC-MS/MS experiment CID and EAD data can be collected, providing information rich fragmentation spectra. The additional information can help in confident localization and identification of metabolites compared to CID alone. These fragments can be crucial to locate the metabolic modification sites, such as conjugations. 
In this study, the application of EAD in drug metabolite profiling is explored. The efficiency in the structural elucidation of conjugation metabolites is compared with that of CID.
Webinar Learning Objectives:
<ul>
<li>Learn how EAD can be advantageous in confident identification and localization of drug metabolites
</li>
<li>Discover the sensitivity of the Zeno trap technology in the identification of the low abundant metabolites
</li>
<li>Explore the capabilities of the Molecule Profiler software in processing EAD and CID data for drug metabolite identification
</li>
</ul>
<blockquote>
Presenter: Ming Yao (Principal Scientist, CPPDB, Bristol-Myers Squibb)
</blockquote>
<blockquote>
Ming Yao currently works at Bristol-Myers Squibb (BMS). He received his B.Sc. from Henan University, and his M.Sc. from the Chinese Academy of Preventive Medicine China. After graduation, he worked at the Institute of Occupational Medicine as an associate professor.
</blockquote>
<blockquote>
As a visiting Associate Professor, he conducted research for bioactivation of chemicals at Merck as well as the University of Western Ontario. After then, he joined BMS and he was responsible for designing and conducting in vitro and in vivo biotransformation studies for multiple programs to support both development and discovery projects. Most recently, he has also been involved in the development of protein drugs, such as the antibody drug conjugates (ADCs) and biotransformation of biologics.
</blockquote>
<blockquote>
Ming has over 28 years of experiences in the pharmaceutical industry and has over 50 publications and 5 book chapters covering new technologies of mass spectrometry and its applications in drug metabolism.
</blockquote>
<blockquote>
Presenter: Rahul Baghla (Manager Pharma Applications, SCIEX)
</blockquote>
<blockquote>
Rahul Baghla, Manager Pharma Applications is a research scientist with 12+ years of experience in various applications of mass spectrometry delivering in Pharma/Biopharma/CRO industries. He is specialised in implementing new mass spectrometry technologies in bioanalytical/analytical method development/validation, drug discovery, ADME assays and clinical studies.
</blockquote>
<blockquote>
He has supported various functions within pharma industry including nutrition, wellness, and oral care based clinical trial studies over the years. Rahul has master’s degree in pharmaceutical analysis, master’s in business administration and a professional diploma in clinical research.
</blockquote>
<blockquote>
He is responsible for continuous engagement with pharmaceutical community to identify major analytical challenges, provide solutions and to find significant analytical opportunities for SCIEX.
</blockquote>

SCIEX: Discover how Bristol-Myers Squibb uses electron-activated dissociation (EAD) to confidently identify drug metabolites and localize site of metabolism.

Discover how Bristol-Myers Squibb uses electron-activated dissociation (EAD) to confidently identify drug metabolites and localize site of metabolism.

Learn how EAD can be advantageous in confident identification and localization of drug metabolites.

LC/MS EAD & drug metabolites & localization of metabolism

Over the last few years, spatial biology has refined the understanding of coordinated biological processes that govern how systems both thrive and become vulnerable to disease.
The latest tools offer advanced images that track the location and types of proteins and RNA across tissue microdomains and cellular phenotypes using a variety of detection techniques but lack the ability to see other post-transcriptional processes defined by metabolites and glycans. MALDI Imaging is a true multiomics technique that allows for spatial determination of metabolites and lipids in tissue, as well as expanding targeted analysis to small molecules, glycans, and proteins. The addition of MALDI-2 and microGRID technology enables imaging for maximum biological information at previously unreachable sensitivity and robust (sub)cellular resolution.
This webinar will introduce how Bruker’s new MALDI HiPLEX-IHC Imaging workflow delivers greater speed and field-of-view for multiplexed protein imaging in tissue, while providing thousands of untargeted molecular images that enable deeper tissue subtyping. The combination of protein spatial localization combined with metabolites and glycans offers a new pathway for coordinated biomarker discovery to complement existing spatial techniques.
What to expect?
<ul>
<li>Live presentation from Bruker’s experts to see ease of use of the timsTOF fleX platform, new MALDI HiPLEX-IHC workflows and highlighting user stories, including focus on improved spatial resolution with microGRID, improved sensitivity with MALDI-2, improved separation selectivity with trapped ion mobility and comprehensive software solutions</li>
</ul>
Who should attend?
<ul>
<li>Anyone using or interested in using tools for spatial biology discovery or translation
</li>
<li>Scientists &amp; researchers interested in expanding their workflows to the spatial dimension, scientists working with spatial distribution of small molecule biologics
</li>
<li>MALDI Imaging users wanting to expand their workflows
</li>
<li>Anyone interested in learning more about MALDI Imaging capabilities
</li>
</ul>
<blockquote>
Presenter: Kate Stumpo, Ph.D. (Senior Market Manager Imaging, Bruker, Billerica, MA, USA)
<ul>
<li>Introduction and welcome to MALDI Imaging </li>
<li>Spatial biology meets Mass Spectrometry in cancer research </li>
<li>MALDI Imaging utility in neurological research</li>
</ul>
</blockquote>
<blockquote>
Presenter: Corinna Henkel, Ph.D. (Application Scientist Imaging, Bruker, Bremen, Germany)
<ul>
<li>MALDI HiPLEX-IHC workflow technical introduction</li>
<li>Software solutions for multiomics integration</li>
</ul>
</blockquote>
<blockquote>
Presenter: Bjoern Wendik, Ph.D. (Business Development Manager, Bruker, Bremen, Germany)
<ul>
<li>Bridging non-MS imaging to the MALDI world</li>
<li>Automation, workflow and relevance for future clinical applications</li>
</ul>
</blockquote>

Bruker: Redefining Hiplexed Spatial Multiomics

Redefining Hiplexed Spatial Multiomics

How Bruker’s new MALDI HiPLEX-IHC Imaging workflow delivers greater speed and field-of-view for multiplexed protein imaging in tissue.

Single-cell proteomics by mass spectrometry can provide valuable insights into distinct cell states and signaling patterns present in a cell population. However, carrying out proteomics profiling from the limited amount of material encapsulated in an individual cell presents significant challenges.
Tremendous efforts have been made to optimize all aspects of single-cell proteomics by mass spectrometry, with the aim of minimizing losses during sample preparation and maximizing sensitivity of data acquisition. Nevertheless, continuous development is needed to increase both the quantifiable proteome depth per cell, the quantitative accuracy and precision of those measurements, and the number of cells measured per unit time.
This webcast will present recently-developed approaches, ranging from sample preparation and chromatographic separation to advanced data acquisition, data interpretation and visualization methods. Advances in instrumentation, including the novel <a href="https://lcms.cz/products/836">Orbitrap Astral MS</a>, and how to use both TMTPro-labeled and label-free approaches, will be presented, showcasing the application of these methods to biomedical questions, and providing an overview of the current technological state of the field.
<h5>Learn how to:</h5>
<ul>
<li>Prepare single cells for analysis by mass spectrometry</li>
<li>Improve the sensitivity and throughput of single-cell proteomics analysis</li>
<li>Implement both label-free and labeled quantitative approaches to single-cell proteomics</li>
</ul>
<blockquote>
Presenter: Dr. Erwin Schoof (Associate Professor, Department of Biotechnology and Biomedicine, Section for Protein Science and Biotherapeutics, Cell Diversity Lab, Technical University of Denmark)
</blockquote>

Metrolab SA: Single-cell proteomics on the Orbitrap Astral MS for the exploration of cell heterogeneity

Single-cell proteomics on the Orbitrap Astral MS for the exploration of cell heterogeneity

This webcast will present recently-developed approaches in single-cell proteomics including the novel Orbitrap Astral MS.

LCMS webinars focusing on LC/HRMS - page 35